MedPath

statin

Generic Name
statin
Clinical Trials
Related News

Low-density Lipoprotein Cholesterol Reduction With State-of-the-art Therapy in Secondary Prevention and Major Cardiovascular Adverse Events: Republic of Srpska Registry

Conditions
Acute Coronary Syndrome
Dyslipidemias
Interventions
First Posted Date
2021-10-18
Last Posted Date
2021-10-25
Lead Sponsor
University Clinical Centre of Republic of Srpska
Target Recruit Count
500
Registration Number
NCT05081336
Locations
🇧🇦

University Clinical Centre of the Republic of Srpska, Banja Luka, Republic Of Srpska, Bosnia and Herzegovina

The Association of Statins on Cardiorespiratory Fitness and Exercise Adaptation

Completed
Conditions
Statin Adverse Reaction
Interventions
Other: Sedentary
Other: Physical activity
First Posted Date
2021-08-02
Last Posted Date
2023-12-01
Lead Sponsor
University of Sao Paulo General Hospital
Target Recruit Count
18557
Registration Number
NCT04986241
Locations
🇧🇷

Marcelo Rodrigues dos Santos, São Paulo, Sao Paulo, Brazil

Statin for Neuroprotection in Spontaneous Intracerebral Hemorrhage

Phase 2
Recruiting
Conditions
Intracerebral Hemorrhage
Statins
Interventions
First Posted Date
2021-04-23
Last Posted Date
2024-01-23
Lead Sponsor
Capital Medical University
Target Recruit Count
98
Registration Number
NCT04857632
Locations
🇨🇳

Beijing Fengtai Youanmen Hospital, Beijing, Beijing, China

🇨🇳

Xuan Wu Hospital，Capital Medical University, Beijing, Beijing, China

🇨🇳

Hebei Province Shunping County Hospital, Baoding, China

Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis

Recruiting
Conditions
Ischemic Stroke
Large-Artery Atherosclerosis (Embolus/Thrombosis)
First Posted Date
2021-04-19
Last Posted Date
2024-06-20
Lead Sponsor
Tongji Hospital
Target Recruit Count
1000
Registration Number
NCT04847752
Locations
🇨🇳

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Oral Statins and Protection From Hearing Loss

Phase 4
Recruiting
Conditions
Sudden Sensorineural Hearing Loss
Interventions
Drug: Placebo
First Posted Date
2021-04-01
Last Posted Date
2024-12-05
Lead Sponsor
Northwestern University
Target Recruit Count
100
Registration Number
NCT04826237
Locations
🇺🇸

Northwestern Memorial Hospital, Chicago, Illinois, United States

Effect of Berberine for Endothelial Function and Intestinal Microflora in Patients With Coronary Artery Disease

Phase 1
Conditions
Stable Coronary Artery Disease
Percutaneous Coronary Intervention
Interventions
First Posted Date
2020-06-16
Last Posted Date
2020-06-16
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
24
Registration Number
NCT04434365
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, Beijing, China

The Benefit of Add On DLBS1033 for Ischemic Stroke Patient

Phase 2
Conditions
Ischemic Stroke
Interventions
Drug: Vit B12
First Posted Date
2020-06-11
Last Posted Date
2020-06-11
Lead Sponsor
Duta Wacana Christian University
Target Recruit Count
180
Registration Number
NCT04425590
Locations
🇮🇩

Bethesda Hospital Yogyakarta, Yogyakarta, Special Region Of Yogyakarta, Indonesia

CHOlesterol Lowering and Residual Risk in Type 2 Diabetes

Phase 4
Completed
Conditions
Type 2 Diabetes
Interventions
Drug: PCSK9 inhibitor
First Posted Date
2020-04-30
Last Posted Date
2024-10-17
Lead Sponsor
NYU Langone Health
Target Recruit Count
151
Registration Number
NCT04369664
Locations
🇺🇸

NYU Langone Health, New York, New York, United States

The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function

Terminated
Conditions
Atrial Fibrillation
Chronic Kidney Disease
Interventions
First Posted Date
2019-08-02
Last Posted Date
2022-08-08
Lead Sponsor
University of Liverpool
Target Recruit Count
56
Registration Number
NCT04043026
Locations
🇬🇧

Liverpool Heart and Chest Hospital, Liverpool, United Kingdom

🇬🇧

Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom

A Study of SCH 58235 (Ezetimibe) When Added to Ongoing Therapy With a Statin in Participants With Primary Hypercholesterolemia, Known Coronary Heart Disease, or Multiple Cardiovascular Risk Factors (P02173)

Phase 3
Completed
Conditions
Primary Hypercholesterolemia
Interventions
Drug: Placebo
Drug: Simivastatin
First Posted Date
2019-03-20
Last Posted Date
2024-05-10
Lead Sponsor
Organon and Co
Target Recruit Count
769
Registration Number
NCT03882905
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy